U.S. Oral Solid Dosage Contract Manufacturing Market Size, Share & Trends Analysis Report By Product, By Mechanism (Immediate Release, Delayed Release), By End Use, By Country And Segment Forecasts, 2025 - 2030
This report can be delivered to the clients within 2 Business Days
U.S. Oral Solid Dosage Contract Manufacturing Market Growth & Trends
The U.S. oral solid dosage contract manufacturing market size is expected treach USD 16.43 billion by 2030, registering a CAGR of 6.1% from 2025 t2030, according ta new report by Grand View Research, Inc. The growth of the market is attributed tfactors such as the increasing pharmaceutical outsourcing and technological advancements in the country. The demand for patient-centric dosage forms has been increasing with time, making it a pivotal trend in the medical field, as it enhances medication adherence. Consequently, manufacturers are producing oral dosage forms that prioritize ease of swallowing.
Trender solid oral drugs more user-friendly, drug sponsors are innovatively transforming drugs intmicror mini tablets and sprinkle capsules. This formulation approach is gaining popularity, especially among the pediatric and geriatric populations. The growing prevalence of chronic and infectious diseases is one of the major factors responsible for the rising demand for novel therapies. Furthermore, the growing geriatric population is contributing tthe rising incidence of chronic diseases, further supporting the demand for novel treatment processes.
Adverse drug reactions texisting drugs are alscontributing tthe demand for novel treatment options. For instance, in July 2022, research published by the University of Liverpool stated that adverse drug reaction-related hospital admissions increased from 6.5% in 2004 t16.5% in 2019. A rise in the number of cases involving adverse drug reactions texisting therapies is expected tboost the demand for new therapies in the future.
For many biopharmaceutical companies, innovations and speed-to-clinic factors are of critical importance. Small companies and specialty biopharmaceutical players increasingly rely upon delivering these important requirements within the industry. Many CROs and CDMOs promote themselves as one-stop-shop companies. The one-stop-shop service model is where a CRO handles everything from API tdosage form and early development tcommercialization. Tprovide these services, a CDMO must have a wide range of enabling technologies and specialized handling capabilities taddress specific problem statements.
Furthermore, increasing undertaking of strategic initiatives by key players is alsexpected tdrive U.S. oral solid dosage (OSD) contract manufacturing market growth. For instance, in January 2023, Catalent and Ethicann collaborated tdevelop Ethicann’s clinical drug pipeline using Catalent’s orally disintegrating tablet (ODT) technology ‘Zydis’. In another instance, in March 2023, Lonza announced that its new clinical and commercial drug product manufacturing line at its Visp site had become fully operational. The expansion is expected tstrengthen the company’s Drug Product Services (DPS) offering.
U.S. Oral Solid Dosage Contract Manufacturing Market Report Highlights
U.S. Oral Solid Dosage Contract Manufacturing Market Growth & Trends
The U.S. oral solid dosage contract manufacturing market size is expected treach USD 16.43 billion by 2030, registering a CAGR of 6.1% from 2025 t2030, according ta new report by Grand View Research, Inc. The growth of the market is attributed tfactors such as the increasing pharmaceutical outsourcing and technological advancements in the country. The demand for patient-centric dosage forms has been increasing with time, making it a pivotal trend in the medical field, as it enhances medication adherence. Consequently, manufacturers are producing oral dosage forms that prioritize ease of swallowing.
Trender solid oral drugs more user-friendly, drug sponsors are innovatively transforming drugs intmicror mini tablets and sprinkle capsules. This formulation approach is gaining popularity, especially among the pediatric and geriatric populations. The growing prevalence of chronic and infectious diseases is one of the major factors responsible for the rising demand for novel therapies. Furthermore, the growing geriatric population is contributing tthe rising incidence of chronic diseases, further supporting the demand for novel treatment processes.
Adverse drug reactions texisting drugs are alscontributing tthe demand for novel treatment options. For instance, in July 2022, research published by the University of Liverpool stated that adverse drug reaction-related hospital admissions increased from 6.5% in 2004 t16.5% in 2019. A rise in the number of cases involving adverse drug reactions texisting therapies is expected tboost the demand for new therapies in the future.
For many biopharmaceutical companies, innovations and speed-to-clinic factors are of critical importance. Small companies and specialty biopharmaceutical players increasingly rely upon delivering these important requirements within the industry. Many CROs and CDMOs promote themselves as one-stop-shop companies. The one-stop-shop service model is where a CRO handles everything from API tdosage form and early development tcommercialization. Tprovide these services, a CDMO must have a wide range of enabling technologies and specialized handling capabilities taddress specific problem statements.
Furthermore, increasing undertaking of strategic initiatives by key players is alsexpected tdrive U.S. oral solid dosage (OSD) contract manufacturing market growth. For instance, in January 2023, Catalent and Ethicann collaborated tdevelop Ethicann’s clinical drug pipeline using Catalent’s orally disintegrating tablet (ODT) technology ‘Zydis’. In another instance, in March 2023, Lonza announced that its new clinical and commercial drug product manufacturing line at its Visp site had become fully operational. The expansion is expected tstrengthen the company’s Drug Product Services (DPS) offering.
U.S. Oral Solid Dosage Contract Manufacturing Market Report Highlights
- Based on product type, the tablets segment captured the highest market share in 2024.This is attributed ttheir widespread use, ease of manufacturing, and strong patient acceptance rate.
- The capsule segment is expected tshow significant market growth in the coming years. Multiple pharmacological ingredients with various release characteristics can be combined in capsules, thus driving their demand.
- Based on the mechanism, the controlled release segment dominated the market in 2024. The controlled release mechanism offers multiple advantages, such as improved efficacy and safety, reduced dosage frequency, and steady blood levels.
- Based on the end-user, the large companies segment dominated the market in 2024. Contract manufacturers generally have the capacity tscale production up or down based on requirement fluctuation. This flexibility can be advantageous for large pharma companies that experience varying levels of demand for their OSD products.
- Medium- and small-sized companies are expected tadvance at a significant growth rate in the coming years. Financial resources are frequently limited for small- and medium-sized companies. Their own manufacturing facilities might be toexpensive tbuild and operate. They can gain cutting-edge production capabilities through contract manufacturing without making a large initial investment.
CHAPTER 1. METHODOLOGY AND SCOPE
1.1. Market Segmentation & Scope
1.2. Segment Definitions
1.2.1. Product
1.2.2. Mechanism
1.2.3. End Use
1.3. Estimates and Forecast Timeline
1.4. Research Methodology
1.5. Information Procurement
1.5.1. Purchased Database
1.5.2. GVR’s Internal Database
1.5.3. Secondary Sources
1.5.4. Primary Research
1.6. Information Analysis
1.6.1. Data Analysis Models
1.7. Market Formulation & Data Visualization
1.8. Model Details
1.8.1. Commodity Flow Analysis
1.9. List of Secondary Sources
1.10. Objectives
CHAPTER 2. EXECUTIVE SUMMARY
2.1. Market Snapshot
2.2. Segment Snapshot
2.3. Competitive Landscape Snapshot
CHAPTER 3. U.S. ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET VARIABLES, TRENDS, & SCOPE
3.1. Market Lineage Outlook
3.2. Market Dynamics
3.2.1. Market Driver Analysis
3.2.2. Market Restraint Analysis
3.3. Business Environment Analysis
3.3.1. Industry Analysis - Porter’s Five Forces Analysis
3.3.1.1. Supplier Power
3.3.1.2. Buyer Power
3.3.1.3. Substitution Threat
3.3.1.4. Threat of New Entrants
3.3.1.5. Competitive Rivalry
3.3.2. PESTLE Analysis
CHAPTER 4. U.S. ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET: PRODUCT BUSINESS ANALYSIS
4.1. Product Market Share, 2024 & 2030
4.2. Product Segment Dashboard
4.3. Market Size & Forecasts and Trend Analysis, by Product, 2018 to 2030 (USD Million)
4.4. Tablets
4.4.1. Tablets Market, 2018 - 2030 (USD Million)
4.5. Capsules
4.5.1. Capsules Market, 2018 - 2030 (USD Million)
4.6. Powders
4.6.1. Powders Market, 2018 - 2030 (USD Million)
4.7. Granules
4.7.1. Granules Market, 2018 - 2030 (USD Million)
4.8. Others
4.8.1. Others Market, 2018 - 2030 (USD Million)
CHAPTER 5. U.S. ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET: MECHANISM BUSINESS ANALYSIS
5.1. Mechanism Market Share, 2024 & 2030
5.2. Mechanism Segment Dashboard
5.3. Market Size & Forecasts and Trend Analysis, by Mechanism, 2018 to 2030 (USD Million)
5.4. Immediate Release
5.4.1. Immediate Release Market, 2018 - 2030 (USD Million)
5.5. Delayed Release
5.5.1. Delayed Release Market, 2018 - 2030 (USD Million)
5.6. Controlled Release
5.6.1. Controlled Release Market, 2018 - 2030 (USD Million)
CHAPTER 6. U.S. ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET: END USE BUSINESS ANALYSIS
6.1. End Use Market Share, 2024 & 2030
6.2. End Use Segment Dashboard
6.3. Market Size & Forecasts and Trend Analysis, by End Use, 2018 to 2030 (USD Million)
6.4. Large Size Companies
6.4.1. Large Size Companies Market, 2018 - 2030 (USD Million)
6.5. Medium & Small Size Companies
6.5.1. Medium & Small Size Companies Market, 2018 - 2030 (USD Million)
6.6. Others
6.6.1. Others Market, 2018 - 2030 (USD Million)
CHAPTER 7. COMPETITIVE LANDSCAPE
7.1. Participant Overview
7.2. Company Market Position Analysis
7.3. Company Categorization
7.4. Strategy Mapping
7.5. Company Profiles/Listing
7.5.1. Catalent, Inc (Novo Holdings A/S)
7.5.1.1. Overview
7.5.1.2. Financial Performance
7.5.1.3. Product Benchmarking
7.5.1.4. Strategic Initiatives
7.5.2. Lonza
7.5.2.1. Overview
7.5.2.2. Financial Performance
7.5.2.3. Product Benchmarking
7.5.2.4. Strategic Initiatives
7.5.3. AbbVie Inc.
7.5.3.1. Overview
7.5.3.2. Financial Performance
7.5.3.3. Product Benchmarking
7.5.3.4. Strategic Initiatives
7.5.4. Aenova Group
7.5.4.1. Overview
7.5.4.2. Financial Performance
7.5.4.3. Product Benchmarking
7.5.4.4. Strategic Initiatives
7.5.5. Adare Pharma Solutions
7.5.5.1. Overview
7.5.5.2. Financial Performance
7.5.5.3. Product Benchmarking
7.5.5.4. Strategic Initiatives
7.5.6. Boehringer Ingelheim International GmbH
7.5.6.1. Overview
7.5.6.2. Financial Performance
7.5.6.3. Product Benchmarking
7.5.6.4. Strategic Initiatives
7.5.7. Jubilant Pharmova Limited
7.5.7.1. Overview
7.5.7.2. Financial Performance
7.5.7.3. Product Benchmarking
7.5.7.4. Strategic Initiatives
7.5.8. Patheon Pharma Services (Thermo Fisher Scientific Inc.)
7.5.8.1. Overview
7.5.8.2. Financial Performance
7.5.8.3. Product Benchmarking
7.5.8.4. Strategic Initiatives
7.5.9. Recipharm AB
7.5.9.1. Overview
7.5.9.2. Financial Performance
7.5.9.3. Product Benchmarking
7.5.9.4. Strategic Initiatives
7.5.10. CordenPharma
7.5.10.1. Overview
7.5.10.2. Financial Performance
7.5.10.3. Product Benchmarking
7.5.10.4. Strategic Initiatives
7.5.11. Siegfried Holding AG
7.5.11.1. Overview
7.5.11.2. Financial Performance
7.5.11.3. Product Benchmarking
7.5.11.4. Strategic Initiatives
1.1. Market Segmentation & Scope
1.2. Segment Definitions
1.2.1. Product
1.2.2. Mechanism
1.2.3. End Use
1.3. Estimates and Forecast Timeline
1.4. Research Methodology
1.5. Information Procurement
1.5.1. Purchased Database
1.5.2. GVR’s Internal Database
1.5.3. Secondary Sources
1.5.4. Primary Research
1.6. Information Analysis
1.6.1. Data Analysis Models
1.7. Market Formulation & Data Visualization
1.8. Model Details
1.8.1. Commodity Flow Analysis
1.9. List of Secondary Sources
1.10. Objectives
CHAPTER 2. EXECUTIVE SUMMARY
2.1. Market Snapshot
2.2. Segment Snapshot
2.3. Competitive Landscape Snapshot
CHAPTER 3. U.S. ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET VARIABLES, TRENDS, & SCOPE
3.1. Market Lineage Outlook
3.2. Market Dynamics
3.2.1. Market Driver Analysis
3.2.2. Market Restraint Analysis
3.3. Business Environment Analysis
3.3.1. Industry Analysis - Porter’s Five Forces Analysis
3.3.1.1. Supplier Power
3.3.1.2. Buyer Power
3.3.1.3. Substitution Threat
3.3.1.4. Threat of New Entrants
3.3.1.5. Competitive Rivalry
3.3.2. PESTLE Analysis
CHAPTER 4. U.S. ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET: PRODUCT BUSINESS ANALYSIS
4.1. Product Market Share, 2024 & 2030
4.2. Product Segment Dashboard
4.3. Market Size & Forecasts and Trend Analysis, by Product, 2018 to 2030 (USD Million)
4.4. Tablets
4.4.1. Tablets Market, 2018 - 2030 (USD Million)
4.5. Capsules
4.5.1. Capsules Market, 2018 - 2030 (USD Million)
4.6. Powders
4.6.1. Powders Market, 2018 - 2030 (USD Million)
4.7. Granules
4.7.1. Granules Market, 2018 - 2030 (USD Million)
4.8. Others
4.8.1. Others Market, 2018 - 2030 (USD Million)
CHAPTER 5. U.S. ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET: MECHANISM BUSINESS ANALYSIS
5.1. Mechanism Market Share, 2024 & 2030
5.2. Mechanism Segment Dashboard
5.3. Market Size & Forecasts and Trend Analysis, by Mechanism, 2018 to 2030 (USD Million)
5.4. Immediate Release
5.4.1. Immediate Release Market, 2018 - 2030 (USD Million)
5.5. Delayed Release
5.5.1. Delayed Release Market, 2018 - 2030 (USD Million)
5.6. Controlled Release
5.6.1. Controlled Release Market, 2018 - 2030 (USD Million)
CHAPTER 6. U.S. ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET: END USE BUSINESS ANALYSIS
6.1. End Use Market Share, 2024 & 2030
6.2. End Use Segment Dashboard
6.3. Market Size & Forecasts and Trend Analysis, by End Use, 2018 to 2030 (USD Million)
6.4. Large Size Companies
6.4.1. Large Size Companies Market, 2018 - 2030 (USD Million)
6.5. Medium & Small Size Companies
6.5.1. Medium & Small Size Companies Market, 2018 - 2030 (USD Million)
6.6. Others
6.6.1. Others Market, 2018 - 2030 (USD Million)
CHAPTER 7. COMPETITIVE LANDSCAPE
7.1. Participant Overview
7.2. Company Market Position Analysis
7.3. Company Categorization
7.4. Strategy Mapping
7.5. Company Profiles/Listing
7.5.1. Catalent, Inc (Novo Holdings A/S)
7.5.1.1. Overview
7.5.1.2. Financial Performance
7.5.1.3. Product Benchmarking
7.5.1.4. Strategic Initiatives
7.5.2. Lonza
7.5.2.1. Overview
7.5.2.2. Financial Performance
7.5.2.3. Product Benchmarking
7.5.2.4. Strategic Initiatives
7.5.3. AbbVie Inc.
7.5.3.1. Overview
7.5.3.2. Financial Performance
7.5.3.3. Product Benchmarking
7.5.3.4. Strategic Initiatives
7.5.4. Aenova Group
7.5.4.1. Overview
7.5.4.2. Financial Performance
7.5.4.3. Product Benchmarking
7.5.4.4. Strategic Initiatives
7.5.5. Adare Pharma Solutions
7.5.5.1. Overview
7.5.5.2. Financial Performance
7.5.5.3. Product Benchmarking
7.5.5.4. Strategic Initiatives
7.5.6. Boehringer Ingelheim International GmbH
7.5.6.1. Overview
7.5.6.2. Financial Performance
7.5.6.3. Product Benchmarking
7.5.6.4. Strategic Initiatives
7.5.7. Jubilant Pharmova Limited
7.5.7.1. Overview
7.5.7.2. Financial Performance
7.5.7.3. Product Benchmarking
7.5.7.4. Strategic Initiatives
7.5.8. Patheon Pharma Services (Thermo Fisher Scientific Inc.)
7.5.8.1. Overview
7.5.8.2. Financial Performance
7.5.8.3. Product Benchmarking
7.5.8.4. Strategic Initiatives
7.5.9. Recipharm AB
7.5.9.1. Overview
7.5.9.2. Financial Performance
7.5.9.3. Product Benchmarking
7.5.9.4. Strategic Initiatives
7.5.10. CordenPharma
7.5.10.1. Overview
7.5.10.2. Financial Performance
7.5.10.3. Product Benchmarking
7.5.10.4. Strategic Initiatives
7.5.11. Siegfried Holding AG
7.5.11.1. Overview
7.5.11.2. Financial Performance
7.5.11.3. Product Benchmarking
7.5.11.4. Strategic Initiatives
